465 results about "Phospholipase" patented technology

The invention provides novel polypeptides having phospholipase activity, including, e.g., phospholipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity, nucleic acids encoding them and antibodies that bind to them. Industrial methods, e.g., oil degumming, and products comprising use of these phospholipases are also provided.

The invention discloses a method of preparing acellular matrixes by using phospholipase. The method of the invention is characterized in that stand-by organ tissue is first pre-treated and then added into solution containing the phospholipase to prepare the acellular matrixes under a controlled condition; the prepared acellular matrixes are then washed. By adopting the preparation method of the invention, the obtained acellular matrix can have good physical property and biological function. Therefore, the preparation method in the invention is not only a great breakthrough in the tissue engineering, but also opens a new way for clinical treatment of diseases. The preparation method of the invention has the advantages of reliable theory, simple and flexible process technique, good product reproducibility and is very easy to be industrialized.

This invention relates to a method for refining crude soybean oil with immobilized phosphatidase. The method solves the problems of unable control of temperature and pH value, poor degumming effect of soybean oil, and high cost faced by the present enzyme degumming method. The method in this invention comprises: preparing the reactive solution, preparing a mixed solution, preparing granular immobilized phosphatidase, pre-treating crude soybean oil, adding immobilized phosphatidase into crude soybean oil, stirring and centrifuging. The method has such advantages as high degumming efficiency (increased by 0.5-2%) and low cost (decreased by 1-3%).

The present invention is directed to a process to remove impurities from triacylglycerol oil including mixing the oil and a fluidic agent, pumping the mixture through a flow-through hydrodynamic cavitation apparatus at a pre-determined inlet pump pressure, creating hydrodynamic cavitation in the mixture, maintaining the hydrodynamic cavitation for a pre-determined period of time, moving the impurities from the oil to the fluidic agent, and then separating the fluidic agent from the oil. The impurities can include phytosterols, sterol glucosides, acylated sterol glucosides, in which case the fluidic agent is water, an alkali hydroxide, an inorganic base, an organic base, phosphoric acid, citric acid, acetic acid or a mixture thereof. The impurities may also include phosphatides, in which case and the fluidic agent comprises water and an enzyme such as phospholipase, a lipid acyltransferase or a mixture thereof.

The present invention relates to a method for identifying therapeutic agents for reducing and monitoring the growth, erosion, rupture or stability of an atherosclerotic plaque comprising the analysis of the differential expression of at least two genes coding proteins chosen among among Stearoyl CoA desaturase, Phosphatidic acid phosphate, and Phosphoinositide-specific-phospholipase-B1, eventually in association with the analysis of the differential expression of at least one gene coding a protein choosen in the group comprising Aldose reductase and aldehyde reductase, Sphingomyelinase, Acid ceramidase, Ceramide glucosyl transferase, Sphingosin phosphate liase, Thymosine beta 4, Aldehyde dehydogenase, ATPase Ca++ binding protein and CD163.

The present invention relates to a method for producing fatty acid alkyl esters, such as fatty acid methyl esters (FAME) and fatty acid ethyl esters with a low level of impurities such as phospholipids. The method of the invention is simplified by combining two process steps into one single process step and is therefore economically cheaper. The method includes mixing water, alcohol, triglyceride and / or free fatty acids a lipolytic enzyme and a phospholipase. Subsequently the aqueous phase, which contains glycerine, residual enzyme and most of the hydrolyzed phospholipids, is separated from the non-aqueous phase, whereby the content of phospholipids in the non-aqueous phase is reduced.

An improved process for enzymatic reducing the content of phosphorus containing components in an edible oil. The method comprises the use of phospholipase and a low amount of water.

The invention discloses a method for preparing GPC by phospholipase-catalyzed hydrolysis and belongs to the technical field of lipid development and application. The method comprises the following steps: preparing GPC by using powdered phospholipid, alcohol soluble phospholipids, high-purity PC as raw materials and by phospholipase-catalyzed hydrolysis of phosphorylcholine (PC) in a water phase; and decolorizing by using active carbon to obtain GPC aqueous solution, converting into an alcohol phase, purifying by using a cation resin adsorption resolution and anion adsorption process to obtain high-purity GPC aqueous solution, performing rotating evaporation at a low temperature and under reduced pressure to obtain colorless transparent L-alpha-GPC solution, wherein the chemical purity of the obtained GPC is 98.8 percent, the optical purity ee of the obtained GPC is 99 percent, and the melting point (mp) of the obtained GPC is 142 to 143 DEG C (C is equal to 2.6, the H2O content is 14 percent and the pH value is 5.8). The invention provides a new thought and a new preparation method for preparing GPC and provides new application of phospholipase in lipid science.

The invention relates to a novel chemical synthesis method of brominated PTP1B inhibitor and the application thereof in the medicine for curing type 2 diabetes, wherein the brominated PTP1B inhibitor has a chemical structural formula as follows: wherein a group connected with 2,2' and the number 3, 3' carbon of benzene ring is bromine atom; 4,4' and the number 5, 5' carbon of the benzene ring are connected with methoxyl; and the PTP1B inhibitor has a chemical name in English: Bis-(2,3-dibromo-4,5-dimethoxy-phenyl)-methane. The compound can enhance the sensibility of insulin receptor by restricting the activity of protein tyrosine phospholipase 1B and has favorable curing effect for type 2 diabetes in insulin resistance types.